Schedule 13G ownership disclosure

Enliven Therapeutics Inc

Common Stock, par value $0.001 per share · CUSIP: 29337E102

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Fairmount Funds Management LLC

    Shares: 3,711,444.00 · Class: 6.3%

  • Fairmount Healthcare Fund II L.P.

    Shares: 3,711,444.00 · Class: 6.3%

  • Peter Harwin

    Shares: 3,711,444.00 · Class: 6.3%

  • Tomas Kiselak

    Shares: 3,711,444.00 · Class: 6.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-078568
Form type
SCHEDULE 13G/A
Filer
Enliven Therapeutics, Inc.
CIK
CIK 1672619
Filed
Aug 14, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub